The goal of the study was to ascertain whether GI adverse events (GI AEs), such as nausea/vomiting, diarrhea, constipation, and dyspepsia (indigestion), during the dose escalation phase (baseline to week 12) and from baseline to the end of treatment, are responsible for the greater weight loss seen with semaglutide compared to other GLP-1RAs
Because Novo Nordisk, the Danish manufacturer of Ozempic and Wegovy, cannot keep up with the surge in demand for the drug, these pharmacies are allowed to peddle their knock-offsfor now
In some cases, it may be best to wait until your symptoms resolve before starting the new GLP-1
The main extra consideration with the injection is the chance of mild injection site reactions
it should always be evaluated professionally